Markets

Otonomy's Ear Infection Drug Otiprio Approved in the U.S.

A generic image of a stock chart
Credit: Shutterstock photo

Otonomy, Inc.OTIC announced that its ear infection drug, Otiprio, was approved in the U.S. for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP).

Otiprio is expected to be available in the U.S. in the first quarter of 2016.

According to information provided by the company, it is estimated that approximately 1 million TTP procedures are performed each year in the U.S., of which 85% are in pediatric patients who typically have middle ear effusion and receive tubes in both ears (bilateral).

Moreover, Otiprio is being evaluated in a phase II study in patients with acute otitis externa, also known as swimmer's ear.

In addition, Otonomy expects to initiate a second phase II study on Otiprio for the treatment of pediatric patients with acute otitis media with tympanostomy tubes in the first quarter of 2016.

We note that Otiprio is the first product approved by the FDA for the abovemention indication.

Otonomy has also updated its financial guidance for 2015. The company expects operating expenses to be below the previous guidance of $65-$60 million. Cash, cash equivalents and short-term investments are expected in the range of $180-$185 million from the previous guidance of $165-$170 million. However, 2016 guidance for operating expenses was maintained at the $90-$95 million range.

Otonomy currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Achillion Pharmaceuticals, Inc. ACHN , Anika Therapeutics Inc. ANIK and Corcept Therapeutics Incorporated CORT , each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CORCEPT THERAPT (CORT): Free Stock Analysis Report

ACHILLION PHARM (ACHN): Free Stock Analysis Report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

OTONOMY INC (OTIC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

OTIC ANIK CORT

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More